AU2005228899A1 - Substituted thiophene derivatives as anti-cancer agents - Google Patents

Substituted thiophene derivatives as anti-cancer agents Download PDF

Info

Publication number
AU2005228899A1
AU2005228899A1 AU2005228899A AU2005228899A AU2005228899A1 AU 2005228899 A1 AU2005228899 A1 AU 2005228899A1 AU 2005228899 A AU2005228899 A AU 2005228899A AU 2005228899 A AU2005228899 A AU 2005228899A AU 2005228899 A1 AU2005228899 A1 AU 2005228899A1
Authority
AU
Australia
Prior art keywords
carboxamide
thiophene
pyrimidin
methylamino
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005228899A
Other languages
English (en)
Inventor
Ann B. Jefferson
Xiaodong Lin
Alice Rico
Annette Walter
Xiaojing Michael Wang
Yasheen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2005228899A1 publication Critical patent/AU2005228899A1/en
Assigned to CHIRON CORPORATION reassignment CHIRON CORPORATION Request for Assignment Assignors: CHIRON CORPORATION, WANG, XIAOJING
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Request for Assignment Assignors: CHIRON CORPORATION
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005228899A 2004-03-30 2005-03-30 Substituted thiophene derivatives as anti-cancer agents Abandoned AU2005228899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55834204P 2004-03-30 2004-03-30
US60/558,342 2004-03-30
PCT/US2005/010690 WO2005095386A1 (en) 2004-03-30 2005-03-30 Substituted thiophene derivatives as anti-cancer agents

Publications (1)

Publication Number Publication Date
AU2005228899A1 true AU2005228899A1 (en) 2005-10-13

Family

ID=34972501

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005228899A Abandoned AU2005228899A1 (en) 2004-03-30 2005-03-30 Substituted thiophene derivatives as anti-cancer agents

Country Status (11)

Country Link
US (2) US7470701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732919A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007531757A (cg-RX-API-DMAC7.html)
CN (1) CN1989131A (cg-RX-API-DMAC7.html)
AU (1) AU2005228899A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0508230A (cg-RX-API-DMAC7.html)
CA (1) CA2561977A1 (cg-RX-API-DMAC7.html)
IL (1) IL177799A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06010520A (cg-RX-API-DMAC7.html)
RU (1) RU2006138036A (cg-RX-API-DMAC7.html)
WO (1) WO2005095386A1 (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20080293716A1 (en) * 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
WO2007018941A2 (en) * 2005-07-26 2007-02-15 Smithkline Beecham Corporation Pyrimidyl-thiophene derivatives
WO2007016292A2 (en) * 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
US7803806B2 (en) 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
ZA200808966B (en) 2006-03-27 2010-03-31 Nerviano Medical Sciences Srl Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
EP2007757B1 (en) 2006-04-13 2012-10-03 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538305A (ja) * 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
CA2652816A1 (en) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
AU2012233017B2 (en) * 2007-02-07 2013-01-10 Novartis Ag Inhibitors of Akt activity
WO2008098105A1 (en) * 2007-02-07 2008-08-14 Smithkline Beecham Corporation Inhibitors of akt activity
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
CN101711245B (zh) * 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
BRPI0818533B8 (pt) * 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl 5-(2-胺基-嘧啶-4-基)-2-芳基-1h-吡咯-3-羧醯胺之製造方法
US20110098221A1 (en) * 2008-06-26 2011-04-28 Hong Lin INHIBITORS OF Akt ACTIVITY
WO2009158374A2 (en) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
NZ594064A (en) 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
KR20120051022A (ko) * 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
TWI491609B (zh) 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科(Flaviviridae)病毒之抑制劑類
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2603214A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
US8741946B2 (en) 2011-07-13 2014-06-03 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
TWI490221B (zh) * 2011-08-15 2015-07-01 武田藥品工業股份有限公司 雜環化合物
ES2617379T3 (es) * 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
HK1214815A1 (zh) * 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CN104262289B (zh) * 2014-10-09 2016-06-08 武汉大学 一种苯并噻唑衍生物及其抗肿瘤用途
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2911888T3 (es) * 2015-09-18 2022-05-23 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos
WO2017063966A1 (en) * 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
CN108884066B (zh) 2016-02-16 2021-08-24 韩国科学技术研究院 作为蛋白激酶抑制剂的2,3,5-取代的噻吩化合物
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
GB201712567D0 (en) 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
CN109400595B (zh) * 2018-12-24 2020-07-17 深圳市第二人民医院 一类含噻吩环的抗癌化合物
AU2020228307A1 (en) * 2019-02-28 2021-09-23 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
CN115536648B (zh) * 2021-06-29 2024-09-17 深圳开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物及其应用
CN114644582B (zh) * 2022-04-11 2024-03-29 中原工学院 一种苯基双硫脲类化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908012A (en) * 1970-10-05 1975-09-23 Pfizer Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6399656B1 (en) * 1998-07-28 2002-06-04 Smithkline Beecham Corporation Compounds and methods
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
JP2002037784A (ja) * 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物
DE10034623A1 (de) * 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
AU2002356871A1 (en) * 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
WO2003086279A2 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7119111B2 (en) * 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
KR20050034732A (ko) * 2002-08-02 2005-04-14 아젠터 디스커버리 리미티드 히스톤 디아세틸라제 억제제로서의 치환된티에닐-히드록사믹산
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20080293716A1 (en) * 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds

Also Published As

Publication number Publication date
RU2006138036A (ru) 2008-05-10
US20080255120A1 (en) 2008-10-16
CA2561977A1 (en) 2005-10-13
JP2007531757A (ja) 2007-11-08
CN1989131A (zh) 2007-06-27
BRPI0508230A (pt) 2007-07-17
EP1732919A1 (en) 2006-12-20
WO2005095386A1 (en) 2005-10-13
US20050256121A1 (en) 2005-11-17
MXPA06010520A (es) 2007-03-26
IL177799A0 (en) 2006-12-31
US7470701B2 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
US7470701B2 (en) Substituted 2,5-heterocyclic derivatives
CN101379060B (zh) 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
KR102155559B1 (ko) 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
US7560467B2 (en) Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
US20100331315A1 (en) Rhodanines and related heterocycles as kinase inhibitors
AU2016280717A1 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
TW200916446A (en) Chiral cis-imidazolines
RS62398B1 (sr) Derivati pirimidina kao modulatori receptora pge2
US20080293716A1 (en) Chemical Compounds
WO2018210987A1 (en) Benzofurane and benzothiophene derivatives as pge2 receptor modulators
TW201900180A (zh) 嘧啶衍生物
RS62440B1 (sr) Derivati fenila kao modulatori receptora pge2
US8796314B2 (en) Heteroaryls and uses thereof
WO2005076854A2 (en) Pyrimidinone compounds useful as kinase inhibitors
CN101258149A (zh) 噻唑衍生物及其应用
JP2024528729A (ja) Srpkインヒビター
HK40051321A (en) Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
HK1168106B (en) Imidazole derivatives as ido inhibitors

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: CHIRON CORPORATION

Free format text: FORMER NAME: CHIRON CORPORATION; WANG, XIAOJING

PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Free format text: FORMER APPLICANT(S): CHIRON CORPORATION

TH Corrigenda

Free format text: IN VOL 22, NO 25, PAGE(S) 2951 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2005 UNDERTHE NAME NOVARTIS VACCINES AND DIAGNOSTICS, INC. DELETE ALL REFERENCE TO 2005228899

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application